Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Reg. 34 (1) Annual Report.

 We wish to inform you that the 27th Annual general meeting of the Company will be held on Thursday 28th July 2022 at 11:00 am through Video-Conferencing. Pursuant to Regulation 34(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Annual Report of the Company for the financial year 2021 - 2022, which has been sent to the members of the Company through electronic mode. The Copy of the report and accounts of the Company for the financial year ended 31st March 2022 together with the Notice are also being uploaded on the Company's website www.bafnapharma.com
06-07-2022
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Statement Of Investor Complaints For The Quarter Ended June 2022

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Roopa RavikumarDesignation :- Company Secretary and Compliance Officer
06-07-2022
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Intimation Of Annual General Meeting And Book Closure Under Regulation 42 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015

 We hereby inform you that 27th Annual General Meeting of the Company is scheduled to be held on Thursday, 28th July 2022. Further, pursuant to Regulation 42 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Register of Beneficial Owners, Register of Members and Share Transfer Books of the Company shall remain closed from 22nd July 2022 to 28th July 2022 (both days inclusive) for the purpose of Annual General Meeting.
05-07-2022
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Closure of Trading Window

 We wish to inform you that pursuant to the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015, the Trading Window for dealing in the Securities of the Company will be closed from 1st day of July 2022 till the end of Forty-Eight (48) hours after the declaration of unaudited Financial Results of the Company for the quarter ending 30th June 2022 The date of Board Meeting of the Company for declaration of the unaudited financial results for the quarter ending 30th June 2022 will be intimated in the due course.
28-06-2022
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Compliances-Reg.24(A)-Annual Secretarial Compliance

 Please find enclosed secretarial compliance report of the Company under Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 issued by M/s A.K JAIN & Associates, Practicing Company Secretaries for the year ending 31st March 2022
28-05-2022
Bigul

Annual report for Bafna Pharmaceuticals Ltd. for FY-2022
27-05-2022
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Outcome of Board Meeting (AGM on July 28, 2022)

 Bafna Pharmaceuticals Ltd has informed BSE regarding Outcome of Board Meeting held on May 26, 2022.
26-05-2022
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Board Meeting Outcome for Outcome Of The Board Meeting Held On 26Th May 2022

 1. AUDITED FINANCIAL RESULTS Approval of audited financial results of the Company for the quarter and year ended 31st March 2022. Please find enclosed the following: 1. Audited financial statements (standalone) for the quarter and year ended 31st March 2022 along with Auditor's report for the said period 2. Declaration on Unmodified Opinion in the Auditors' Report for Financial Year ended March 31, 2022 2. ANNUAL GENERAL MEETING The 27th Annual General Meeting of the members of the Company is scheduled to be held on Thursday, 28th July 2022 at 12:00 Noon through video conferencing and other audio visual means. 3. To open wholly owned subsidiary of Bafna Pharmaceuticals Limited in Australia.
26-05-2022
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Board Meeting Intimation for Intimation Of Board Meeting Of The Company To Inter-Alia Consider And Approve The Audited Financial Results For The Quarter / Year Ending 31St March 2022

 BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2022 ,inter alia, to consider and approve We would like to inform that meeting of the Board of Directors of the Company will be held on Thursday, 26th May 2022 to inter alia consider and adopt audited financial results for the quarter / year ended 31st March 2022 and any other business with the permission of the Chair. Further in accordance with the Code of Conduct for prevention of Insider Trading pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the trading window for dealing in securities of the Company has already been closed from 1st April 2022 and shall remain closed until 48 hours after the financial results approved at the meeting are made public.
20-05-2022
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2

 Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company BAFNA PHARMACEUTICALS LTD. 2 CIN NO. L24294TN1995PLC030698 3 Report filed for FY 2021-2022 Details of the Current block (all figures in Rs crore): 4 2 - year block period (Specify financial years)* 2021-2022,2022-23 5 Incremental borrowing done in FY (T)(a) 1.27 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) 0 8Quantum of (d), which has been met from (c)(e)* 0 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* 0 Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)2021-2022,2022-2023 Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00 Name of the Company Secretary :-Roopa RavikumarDesignation :-Company Secretary Name of the Chief Financial Officer :- M SRIDHAR Designation : -CHIEF FINANCIAL OFFICER Date: 09/05/2022
09-05-2022
Next Page
Close

Let's Open Free Demat Account